Abstracts tagged "gout"

Abstract Number: 2967 • 2018 ACR/ARHP Annual Meeting
Potent Bifunctional Inhibitors of Xanthine Oxidase and URAT1 Block Fructose-Induced Inflammation Via Increase in AMP Kinase Activity
Laura Gabriela Sánchez Lozada¹, Fernando E. García-Arroyo², J. Gabriel Juárez-Rojas³, Guillermo Gonzaga² and Raymond P. Warrell Jr.⁴, ¹Nephrology, INC Ignacio Chavez, Mexico City, Mexico, ²INC Ignacio Chavez, Mexico City, Mexico, ³INC Ignacio Chavez, Mexoci City, Mexico, ⁴Relburn-Metabolomics, Inc., Westfield, NJ
Background/Purpose: Dietary fructose promotes an increase in uric acid (UA) that may lead to gout. UA itself promotes lipogenesis and inflammation in both gout as…
Abstract Number: 433 • 2018 ACR/ARHP Annual Meeting
Impact of Bariatric Surgery on Rheumatic Diseases: A Systematic Review and Meta-Analysis
Marie Moly¹, Bernard Combe¹, Thomas Barnetche², Claire Daien¹, Jacques Morel³, Cédric Lukas¹, Cécile Gaujoux-Viala⁴ and Charlotte Hua⁴, ¹Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ²Rheumatology, University Hospital Pellegrin, Bordeaux, Bordeaux, France, ³Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁴Rheumatology, University Hospital Carémeau , Nimes, Nimes, France
Background/Purpose: Obesity increase the incidence of rheumatic diseases (1-3). Bariatric surgery (BS) improve obesity-related comorbidities (4). The aim of our study was to assess currently…
Abstract Number: 1265 • 2018 ACR/ARHP Annual Meeting
The Challenges of Managing Gout in Primary Care: Results of a Best Practice Audit
Lisa K. Stamp¹, Peter T. Chapman², Ben Hudson³, Greg Hamilton⁴ and Andrea Judd⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand, ⁴Canterbury District Health Board, Christchurch, New Zealand, ⁵Kaikoura Medical Centre, Kaikoura, New Zealand
Background/Purpose: The majority of gout management occurs in primary care and may be suboptimal. While community based clinical trials have reported improvements whether such improvements…
Abstract Number: 2222 • 2018 ACR/ARHP Annual Meeting
Construct Validity of Provisional Remission Criteria for Gout: A Dual Energy CT Study
Nicola Dalbeth¹, Christopher Frampton², Maple Fung³, Scott Baumgartner³, Savvas Nicolaou⁴ and Hyon K. Choi⁵, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, New Zealand, ³Formerly Ardea Biosciences, San Diego, CA, ⁴Radiology, University of British Columbia, Vancouver, BC, Canada, ⁵Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Provisional domains and definitions for gout remission criteria have been proposed using consensus methodology (de Lautour et al, Arthritis Care Res 2016). These criteria…
Abstract Number: 869 • 2018 ACR/ARHP Annual Meeting
Failure to Reach Serum Urate Target Is Associated with Elevated Mortality in Gout
Fernando Perez-Ruiz^1,2,3, Pascal Richette^4,5, Austin Stack⁶, Ravichandra Karra Gurunath⁷, MARIA JESUS GARCIA DE YEBENES Y PROUS⁸ and Loreto Carmona⁹, ¹Rheumatology Division, Hospital Universitario Cruces, Baracaldo, Spain, ²University of the Basque Country (UPV/EHU), Bilbao, Spain, ³BioCruces Health Research Institute, Barakaldo, Spain, ⁴Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ⁵Rheumatology, Université Paris Diderot, Paris, France, ⁶Nephrology, University Hospital Limerick & Health Research Institute,University of Limerick, Limerick, Ireland, ⁷Grünenthal GmbH, Aachen, Germany, ⁸Institute for Musculoskeletal Health, Madrid, Spain, ⁹Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain
Background/Purpose: Gout is associated with an increased risk of cardiovascular events and death. It has been shown that both overall and risk of death are…
Abstract Number: 1271 • 2018 ACR/ARHP Annual Meeting
Predictive Factors of Increased Vascular Stiffness in Patient with Gout and Hyperuricemia
WooSeong Jeong¹, Jinseok Kim², Joon Hyouk Choi³ and Byeongzu Ghang¹, ¹Division of Rheumatology, Department of Internal Medicine, Jeju National University Hospital, University of Jeju School of Medicine, Jeju, Korea, Republic of (South), ²Department of Medicine, Jeju National University Hospital, University of Jeju School of Medicine, Jeju, Korea, Republic of (South), ³Division of Cardiology, Department of Internal Medicine, Jeju National University Hospital, University of Jeju School of Medicine, Jeju, Korea, Republic of (South)
Background/Purpose: Background: Gout is the most common form of inflammatory arthritis and its prevalence is increasing in more affluent countries in recent decades. Many studies…
Abstract Number: 2228 • 2018 ACR/ARHP Annual Meeting
A Validated Script Concordance Test Demonstrates Interdisciplinary Differences in Clinical Decision-Making When Using Allopurinol to Treat Gout in Chronic Kidney Disease
Nicholas Lebedoff¹, Sarah Gilligan¹, Andrea Barker², Curry L. Koening³, Kelly Starman⁴, Christina Gallop⁵, Bernadette C. Siaton⁶, Kalani L. Raphael^4,7 and Michael J. Battistone⁸, ¹Internal Medicine, University of Utah, Salt Lake City, UT, ²Salt Lake City VAMC and University of Utah, North Salt Lake, UT, ³Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁴Salt Lake City VA Medical Center, Salt Lake City, UT, ⁵Primary Care, Salt Lake City VA Medical Center, Salt Lake City, UT, ⁶University of Maryland, Baltimore, MD, ⁷Nephrology, University of Utah, Salt Lake City, UT, ⁸Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: The safety of allopurinol in the setting of chronic kidney disease (CKD) has been a controversial issue for many years. The perceived increased risk…
Abstract Number: 870 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Burden of Gout in 2017 from the United States
Puja P. Khanna¹, Douglas C.A. Taylor², An-Chen Fu² and Robert Morlock³, ¹University of Michigan, Ann Arbor, MI, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA, ³YourCareChoice, Ann Arbor, MI
Background/Purpose: Gout is reported to impact 3.9% of the US adult population (Zhu. Arthritis Rheum 2011;63:3136-41). Treatment encompasses controlling acute attacks (flares) and, dependent on…
Abstract Number: 1272 • 2018 ACR/ARHP Annual Meeting
Quality of Gout Management in a Rheumatology Clinic Using a Provider-Pharmacist Team-Based Approach
Jessica Michaud¹ and Jenna Beatty², ¹Pharmacy, Froedtert & the Medical College of Wisconsin, Milwaukee, WI, ²University of Kansas, kansas city, MO
Background/Purpose: Gout is the most common form of inflammatory arthritis.1 The cornerstone of treatment for gout is urate-lowering therapy (ULT), which in the U.S. includes…
Abstract Number: 2237 • 2018 ACR/ARHP Annual Meeting
Prevalence of Urate-Lowering Therapy Use and Target Urate Level Achievement Among Gout Patients in the United States (National Health And Nutrition Examination Survey [NHANES] 2007-2014)
Michael Chen-Xu¹, Chio Yokose², Michael Pillinger³ and Hyon K. Choi², ¹General Medicine, Wairarapa District Health Board, Masterton, New Zealand, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ³Medicine/Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: To determine the latest national prevalence of urate-lowering therapy (ULT) use and achievement of a therapeutic target serum urate level (SUL) in gout patients,…
Abstract Number: 871 • 2018 ACR/ARHP Annual Meeting
Estimates of Diet Quality Explain Less Variability in Serum Urate Levels Than Genetic Factors
Tanya J. Major¹, Ruth Topless¹, Nicola Dalbeth² and Tony R. Merriman¹, ¹University of Otago, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand
Background/Purpose: Hyperuricaemia (elevated serum urate) is a central risk factor for gout, an acute inflammatory form of arthritis. The balance between the hepatic production of…
Abstract Number: 1273 • 2018 ACR/ARHP Annual Meeting
What Did Patients from the US Think about Their Gout in 2017?
Puja P. Khanna¹, Douglas C.A. Taylor², An-Chen Fu² and Robert Morlock³, ¹University of Michigan, Ann Arbor, MI, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA, ³YourCareChoice, Ann Arbor, MI
Background/Purpose: The impact of chronic gout and acute flares on daily activities is severely limiting. Yet only 40% of gout patients receive urate-lowering therapy (ULT),…
Abstract Number: 2241 • 2018 ACR/ARHP Annual Meeting
What Can Variation in Clinical Practice Teach Us about Treatment Strategies for Patients with Gout?
Ritch te Kampe¹, Caroline van Durme¹, Matthijs Janssen², Annelies Boonen¹ and Tim Jansen², ¹Department of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands, Maastricht, Netherlands, ²Department of Rheumatology, VieCuri Medical Center, Venlo, The Netherlands, Venlo, Netherlands
Background/Purpose: To improve quality of care for patients with gout, two hospitals in the Netherlands initiated a protocolized gout clinic. One clinic adopted a patient-centred…
Abstract Number: 872 • 2018 ACR/ARHP Annual Meeting
Is the Serum Uric Acid Therapeutic Target Protective of Chronic Kidney Disease, Cardiovascular Disease, and Mortality for Patients with Gout? a Longitudinal Study
Douglas C.A. Taylor¹, Dena Jaffe², Moshe Hoshen³, Galit Shefer³, Asaf Bachrach³, Becca Feldman³, An-Chen Fu¹ and Hyon K. Choi⁴, ¹Ironwood Pharmaceuticals, Inc., Cambridge, MA, ²Kantar Health, Tel Aviv, Israel, ³Clalit Research Institute, Tel Aviv, Israel, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Many studies have found that serum uric acid (sUA) levels are associated with the incidence of chronic kidney disease (CKD), cardiovascular disease (CVD), and…
Abstract Number: 1275 • 2018 ACR/ARHP Annual Meeting
Dual-Energy CT for the Diagnosis of Gout: A Prospective Study in Patients with No Prior History of Gout
Mihaela Gamala¹, Johannes W. G. Jacobs², Suzanne Linn-Rasker³, Maarten Nix⁴, Ben Heggelman⁴, Pieternel Pasker⁵, Jacob van Laar⁶ and Ruth Klaasen³, ¹Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology, Meander Medical Center Amersfoort, Amersfoort, Netherlands, ⁴Radiology, Meander Medical Center Amersfoort, Amersfoort, Netherlands, ⁵Meander Academy, Meander Medical Center Amersfoort, Amersfoort, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands
Background/Purpose: Gout is associated with joint damage, and increased cardiovascular morbidity, so to diagnose and treat gout early is important. However, joint aspiration and microscopy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].